Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial

  1. Mateos, M.-V.
  2. Nahi, H.
  3. Legiec, W.
  4. Grosicki, S.
  5. Vorobyev, V.
  6. Spicka, I.
  7. Hungria, V.
  8. Korenkova, S.
  9. Bahlis, N.
  10. Flogegard, M.
  11. Bladé, J.
  12. Moreau, P.
  13. Kaiser, M.
  14. Iida, S.
  15. Laubach, J.
  16. Magen, H.
  17. Cavo, M.
  18. Hulin, C.
  19. White, D.
  20. De Stefano, V.
  21. Clemens, P.L.
  22. Masterson, T.
  23. Lantz, K.
  24. O'Rourke, L.
  25. Heuck, C.
  26. Qin, X.
  27. Parasrampuria, D.A.
  28. Yuan, Z.
  29. Xu, S.
  30. Qi, M.
  31. Usmani, S.Z.
  32. Show all authors +
Journal:
The Lancet Haematology

ISSN: 2352-3026

Year of publication: 2020

Volume: 7

Issue: 5

Pages: e370-e380

Type: Article

DOI: 10.1016/S2352-3026(20)30070-3 GOOGLE SCHOLAR

Sustainable development goals